Statements (46)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:HealthCorp
|
| gptkbp:awards |
Best Startup 2020
Innovation Award 2021 Excellence in Research 2022 |
| gptkbp:CEO |
gptkb:John_Doe
|
| gptkbp:clinicalTrials |
Ongoing
Phase 1 Phase 2 Phase 3 |
| gptkbp:collaboratesWith |
gptkb:Research_Institute
Clinical_Research_Organization Biotech_Company |
| gptkbp:develops |
Medications for neurological disorders
|
| gptkbp:employees |
200
|
| gptkbp:focusesOn |
Neurology
|
| gptkbp:foundedIn |
2006
|
| gptkbp:funding |
Series A
Series B Series C |
| gptkbp:headquarters |
gptkb:New_York,_USA
|
| https://www.w3.org/2000/01/rdf-schema#label |
Serenity Pharmaceuticals
|
| gptkbp:investmentFocus |
Venture_Capital_Group
|
| gptkbp:market |
gptkb:Asia
gptkb:North_America Europe |
| gptkbp:mission |
Improve patient outcomes
|
| gptkbp:partnerships |
gptkb:University_of_Medicine
|
| gptkbp:patentCitation |
10
|
| gptkbp:products |
Serenity-1
Serenity-2 Serenity-3 |
| gptkbp:researchFocus |
Multiple Sclerosis
Parkinson's Disease Alzheimer's Disease |
| gptkbp:revenue |
50 million USD
|
| gptkbp:socialResponsibility |
Research Grants
Sustainability Practices Patient Advocacy Programs Community_Health_Initiatives |
| gptkbp:values |
Collaboration
Innovation Integrity Excellence |
| gptkbp:vision |
Leading in neurology treatments
|
| gptkbp:website |
www.serenitypharma.com
|